Genetic testing for prevention of severe drug-induced skin rash-Reference-Cited by-同舟云学术

Genetic testing for prevention of severe drug-induced skin rash

Published:2019-07-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Alfirevic Ana¹,Pirmohamed Munir¹,Marinovic Branka²,Harcourt-Smith Linda³,Jorgensen Andrea L⁴,Cooper Tess E⁵

Affiliation:

1. Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Centre for Personalised Medicine, Block A: Waterhouse Building 1-5 Brownlow Street Liverpool UK L69 3GE

2. University Hospital Centre Zagreb, School of Medicine, University of Zagreb; Department of Dermatology and Venereology; Salata 4 Zagreb Croatia 10000

3. The University of Nottingham; c/o Cochrane Skin Group; A103, King's Meadow Campus Lenton Lane Nottingham UK NG7 2NR

4. University of Liverpool; Centre for Medical Statistics and Health Evaluation; Shelley's Cottage Brownlow Street Liverpool UK L69 3 GS

5. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010891.pub2/epdf/full

Reference79 articles.

1. PREDICT-1 (CNA106030): The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events;Hughes;Pharmaceutical Statistics,2008

2. HLA-B*5701 screening for hypersensitivity to abacavir;Mallal;New England Journal of Medicine,2008

3. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy;Azuma;European Journal of Clinical Pharmacology,2013

4. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial;Bonnefoi;Lancet Oncology,2011

5. New testing approach in HLA genotyping helps overcome barriers in effective clinical practice;Cheng;Clinical Chemistry,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV;Pharmacogenomics;2023-09-28

2. Lip synechiae: A sequelae of carbamazepine‐induced erythema multiforme. A case report and review of current perspectives and controversies;Oral Surgery;2023-03-31

3. Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database;Pharmacogenomics and Personalized Medicine;2022-11

4. Pharmacogenomics of Drug Hypersensitivity;Immunology and Allergy Clinics of North America;2022-05

5. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study;The Lancet Oncology;2022-01